Zantac and Uptravi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zantac (ranitidine hydrochloride) and Uptravi (selexipag). Common drug interactions include abdominal pain upper among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Zantac and Uptravi. It is created by eHealthMe based on reports of 58 people who take the same drugs from the FDA, and is updated regularly.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.

What is Uptravi?

Uptravi has active ingredients of selexipag. eHealthMe is studying from 26,576 Uptravi users. Check the latest studies of Uptravi.



On Jul, 06, 2026

58 people who take Zantac and Uptravi together, and have interactions are studied.

Zantac and Uptravi drug interactions.

What are the common drug interactions of Zantac and Uptravi, by gender? *:

female:

  1. Abdominal pain upper
  2. Fluid overload (too much fluid in the blood)
  3. Influenza
  4. Lymphadenopathy (disease or enlargement of lymph nodes)
  5. Osteoporosis (bones weak and more likely to break)
  6. Hospitalisation
  7. Pain
  8. Pain in extremity
  9. Pulmonary hypertension (increase in blood pressure in the lung artery)
  10. Stent placement

male:

  1. Diarrhoea
  2. Headache (pain in head)
  3. Limb discomfort (discomfort in leg)
  4. Oedema peripheral (superficial swelling)
  5. White blood cell count decreased
  6. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  7. Back pain
  8. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
  9. Dysphemia (stammering or stuttering)
  10. Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Zantac and Uptravi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Abdominal pain upper
  2. Arrhythmia (irregular heartbeat)
  3. Atrial flutter (an abnormal heart rhythm that occurs in the atria of the heart)
  4. Dyspnoea (difficult or laboured respiration)
  5. Oropharyngeal pain
  6. Right atrial dilatation (enlargement of the right atrium chamber of heart)
  7. Right ventricular dysfunction
  8. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

20-29:

n/a

30-39:

  1. Headache (pain in head)
  2. Hospitalisation
  3. Migraine (headache)

40-49:

  1. Fluid retention (an abnormal accumulation of fluid in the blood)
  2. Headache (pain in head)
  3. Vomiting
  4. Abdominal distension
  5. Abdominal pain
  6. Diarrhoea
  7. Dyspnoea (difficult or laboured respiration)
  8. Flushing (the warm, red condition of human skin)
  9. Hypertension (high blood pressure)
  10. Sinusitis (inflammation of sinus)

50-59:

  1. Abdominal pain
  2. Abdominal pain upper
  3. Arthralgia (joint pain)
  4. Blood creatinine increased
  5. Blood glucose increased
  6. Blood pressure increased
  7. Blood urine present
  8. Breast cancer stage iii
  9. Cardiomegaly (increased size of heart than normal)
  10. Cataract (clouding of the lens inside the eye)

60+:

  1. Diarrhoea
  2. Vomiting
  3. Oxygen saturation decreased
  4. Blood creatinine increased
  5. Haemoglobin decreased
  6. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  7. Dyspnoea (difficult or laboured respiration)
  8. Gastritis (inflammation of stomach)
  9. Localised oedema (fluid retention in a particular part of the body)
  10. Pulmonary oedema (fluid accumulation in the lungs)

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 40 people, 68.97%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 6 people, 10.34%
  3. Indigestion: 4 people, 6.90%
  4. Connective Tissue Disorder (any disease that has the connective tissues of the body): 3 people, 5.17%

* Approximation only. Some reports may have incomplete information.

Do you take Zantac and Uptravi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Zantac and Uptravi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zantac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Uptravi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zantac and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Uptravi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine hydrochloride and selexipag (the active ingredients of Zantac and Uptravi, respectively), and Zantac and Uptravi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: